Skip to main content
CDC Website

Other Health-Related

Limited Competition: Revision Applications of Existing NIH Centers for AIDS Research (CFAR) and Developmental Centers for AIDS Research (D-CFAR) Grants (P30 Clinical Trial Not Allowed)

This notice of funding opportunity (NOFO) encourages revision applications from currently funded NIH Centers for AIDS Research (CFAR) and Developmental CFARs (D-CFAR) to expand the role of the CFARs and D-CFARs to include additional support and infrastructure for outreach and research related to HIV and HIV-related health disparities in the United States and globally. The goal of the NOFO is aimed towards diversifying and supporting the next generation of HIV/AIDS investigators, and engaging and mentoring these investigators in high-priority HIV/AIDS research.

Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)

This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches.

Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)

This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches.

Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)

This initiative will support multilevel and multidisciplinary intervention research to improve quality of life and promote successful aging among people with HIV with HIV associated non-AIDS comorbidities across the life course from racial and ethnic and lower socioeconomic status groups.

Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to identify cure strategies suitable for administration at the start of combination antiretroviral therapy (cART) and/or at cART restart after an analytical treatment interruption (ATI), with the ultimate goal of achieving sustained treatment-free remission.

Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed

The purpose of this Notice of Funding Opportunity (NOFO) is to identify cure strategies suitable for administration at the start of combination antiretroviral therapy (cART) and/or at cART restart after an analytical treatment interruption (ATI), with the ultimate goal of achieving sustained treatment-free remission.

Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)

The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, serum, and genomic DNA) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This opportunity allows investigators to apply for access to the biospecimens from the PATH Study.

Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of a comprehensive and well-defined product development strategy for next-generation treatments for HIV and HIV-associated comorbidities, coinfections and complication and preventive strategies for HIV, as well as facilitating the translation of research findings into drug products that enables submission of an Investigational New Drug (IND) application to the FDA.

Notice of Special Interest (NOSI): Advancing Biomedical Research in Pulmonary Non-Tuberculosis Mycobacterial (NTM) Infections

This NOSI aims to stimulate advances in diagnosis and treatment of NTM infections that cause or exacerbate pulmonary disease such as Mycobacterium abscessus, Mycobacterium avium complex, and Mycobacterium kansasii.  Areas of interest include but are not limited to: